It’s the leading cause of disability due to pain and the most common form of arthritis, afflicting an estimated 237 million people worldwide. Osteoarthritis (OA) occurs as the cartilage on the end of bones wears down and most often affects the hands, knees, hips, and spine – though it can damage any joint in the body.
Treating the chronic pain patients experience is among the most enduring challenges in analgesic drug development. In this webinar, the speakers examined:
- Osteoarthritis as a flexible model for development of new therapies
- Design of clinical trial protocols to address the special needs of the drug being studied
- Study design features that reduce placebo effects
- Typical efficacy scales in OA studies
- Common data analysis methods